Might be ready for another leg to new highs, page-12

Now that we have more clarity around cargo priorities going forward its interesting to look back at the 'target customers' identified in the AGM presentation from 2017.

More specifically, looking at the flagship priority from the Operations Update 3Q 2018, we can highlight two particular target customers. The space is anti-sense oligonucleotides. The customers in the space are BioMarin and Astellas and the disease indication is DMD.

BioMarin was highlighted by Hottod back in December 2017 and is indeed 'an interesting inclusion'. It ticks lots of boxes and may have a point to prove. One reason being that it shelved a DMD drug following a US$680m gamble on Drisapersen. Intracellular delivery may be all it needs to revisit its program for DMD.